News | June 15, 2024
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
EDQM has also issued a Certificate of Suitability for Allopurino
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Subscribe To Our Newsletter & Stay Updated
